NervGen Announces First Participant Dosed in RESTORE, a Phase 3 Registrational Study Evaluating NVG-291 in Chronic Spinal Cord Injury

Cite

APA MLA Chicago

NervGen Announces First Participant Dosed in RESTORE, a Phase 3 Registrational Study Evaluating NVG-291 in Chronic Spinal Cord Injury. (2026, October 12). Toronto Star. https://www.thestar.com/globenewswire/nervgen-announces-first-participant-dosed-in-restore-a-phase-3-registrational-study-evaluating-nvg-291/article_bb6b620d-0d27-527d-8cda-1ddc666fc659.html

Dated when The Aporia collected the article, usually within hours of publication. Check the original for its exact date and byline.

Toronto Star · collected 2026-10-12 · by GlobeNewswire, Inc.

Quick Summary

NervGen has announced that the first participant has been dosed in RESTORE, a Phase 3 study assessing NVG-291 for improving hand function and quality of life in individuals with chronic cervical motor-incomplete spinal cord injury. The study builds on previous positive results from the CONNECT SCI trial and is aligned with FDA guidelines. Enrollment completion is expected in the second half of 2027, with topline data anticipated by the first half of 2028.

Written by AI on 2026-10-12, from this article's own text only (the story summary below draws on all the coverage).

AI analysis

Story summary

NervGen, a biopharmaceutical company focused on neuroreparative therapies, announced that the first patient has been enrolled in RESTORE, a Phase 3 study for NVG-291, a drug aimed at improving hand function and quality of life for individuals with chronic cervical motor-incomplete spinal cord injuries. This trial builds upon earlier positive results from the Phase 1b/2a CONNECT SCI study, which showed functional improvements. The FDA has aligned with this design for the Phase 3 registrational study. NervGen expects to complete patient enrollment by the second half of 2027 and release initial data in the first half of 2028.

Written for “NervGen Clinical Trial Update” on 2026-11-01, grounded in this article and the 0 other(s) covering the same event.

Story

📰 NervGen Clinical Trial Update

Health · 1 article(s) covering the same event.

Compared with similar articles

Nothing to compare against. No article is close enough to this one for the pipeline to have linked or judged the pair.

How this article was measured signals, leaning charts, publisher record, byline, topics and claims

Signals How these are calculated →

Claims extracted

sentences that state something as happening or true

Uncertain

0 of 3 hedged ("reportedly", "may", "according to")

Leaning

not political

takes no side on a contested political question

Publisher signals

64/100

Toronto Star's corrections and hedging, across everything collected from it. Not a measure of accuracy.

Outlets on this story

Health

Same framing elsewhere

articles that frame the event the way this one does

Analyzed 2026-10-12 · how these are computed

How this is being covered How these are calculated →

Article leaning vs. publisher reliability

Source leaning vs. consistency

Publisher

Toronto Star · 11011 article(s) · 28 correction(s) detected

Running correction rate · 28 correction(s)

2026-10-31

Inmate's escape is just the latest problem for Tennessee's troubled prison system

2026-10-26

Correction

2026-10-24

Correction

2026-10-22

News Clarification for Oct. 22

2026-10-21

No. 6 Hoosiers try to for rare rebound at Michigan after turning the page on 22-game winning streak

2026-10-19

Driver’s License Suspensions for Court Debt Draw Scrutiny

2026-10-16

Amputations and cancer treatment delays: Lawmakers hear testimony on Mississippi prison healthcare

2026-10-16

UPDATE: Golconda Gold Releases Q3 2026 Production Update at Galaxy

2026-10-08

News Clarification for Oct. 8

2026-10-07

Correction

2026-10-05

Entertainment Correction for Oct. 5

2026-10-03

Tennessee's prisons chief is resigning after failed execution of Christa Pike

2026-09-28

Organizations call for Action to End the Deaths of Indigenous People in Custody

2026-09-27

Police memorial recognizes six officers killed in the line of duty in 2026

2026-09-27

UPDATE: WSP to host Power & Energy-focused investor event virtually only

2026-09-26

News Clarification for Sept. 27

2026-09-26

Former federal public servant seeks better pensions for injured workers

2026-09-25

News Corrections for Sept. 25

2026-09-25

She has not been charged. But the Project South allegations have branded her with a 'scarlet letter'

2026-09-24

Correction

2026-09-23

MULTIMEDIA UPDATE: Smith+Nephew launches the new EVOS™ PELVIC Plating System at the 2026 Orthopedic Trauma Association (OTA) Annual Meeting, expanding the EVOS Plating Platform for pelvic and acetabular fracture management

2026-09-22

Costa Rican man complained of lack of care for diabetes before his death in ICE custody, family says

2026-09-22

Judges' grilling of accused men leads to sex assault and dangerous driving cases being overturned

2026-09-20

Jura Energy Corporation Provides Clarification Regarding Media Reports Concerning Its Petroleum Rights in Pakistan

2026-09-19

New details emerge about Toronto's guns-for-hire and the 'crash-out mission" that sparked the Project South investigation

2026-09-17

UPDATE: Osisko Critical Minerals Corporation Announces C$100 Million Private Placement of Special Warrants

2026-09-17

Alabama set to execute man for pawn shop killings months after his nitrogen gas execution blocked

2026-09-04

Orca Corrects Q3 Quarterly Dividend Announcement

Who wrote this

No reporter is named on this article, beyond the feed's “GlobeNewswire, Inc.”.

Topics

FDA MIAMI NGEN NervGen RESTORE

Subjects

NervGen ORG · 2× FDA ORG · 1× MIAMI GPE · 1× NGEN ORG · 1× RESTORE ORG · 1×

Narrative

- RESTORE is evaluating NVG-291’s potential to improve hand function and quality of life in individuals living with chronic cervical motor-incomplete spinal cord injury - Study builds on functional improvements observed in the placebo-controlled Phase 1b/2a CONNECT SCI study, with FDA alignment on the Phase 3 registrational design - Enrollment completion anticipated in the second half of 2027; topline data expected in the first half of 2028 MIAMI, Oct. 12, 2026 (GLOBE NEWSWIRE) —

framing: assertive · carried by 1 article(s) · first seen 2026-10-12

2026-10-12 · Toronto Star

NervGen Announces First Participant Dosed in RESTORE, a Phase 3 Registrational Study Evaluating NVG-291 in Chronic Spinal Cord Injury · assertive framing

Claims (3 extracted, 0 hedged)

data → evaluate → 2028

NervGen (NASDAQ: NGEN), a late-stage clinical biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions, today announced that the first participant has been dosed in RESTORE, a Phase 3 registrational study evaluating NVG-291 in individuals living with chronic cervical motor-incomplete SCI. asserted

participant → develop → SCI

NervGen anticipates completing enrollment in the second half of 2027 and reporting topline data in the first half of 2028. asserted

NervGen → complete → 2028

💬Give feedback

🕘History 🎫Support

Terms · Privacy · beta v2.0.0

Articles to 1 Nov 2026